SEC Form 4 · accession 0001209191-18-009144
Ignyta, Inc. · RXDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven L. Hoerter
Director
Period of report
Feb 8, 2018
Accepted (ET)
Feb 12, 2018 · 3:31 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001557421
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $6.40 | Feb 8, 2018 | D | 24,000 | D | — | Dec 7, 2026 | Common Stock | 24,000 | 0 | D |
| Stock Option (Right to Buy)F1 | $8.35 | Feb 8, 2018 | D | 11,666 | D | — | Jun 12, 2027 | Common Stock | 11,666 | 0 | D |
Explanation of responses
- F1In connection with the acquisition of the Issuer by Roche Holdings, Inc. ("Parent") on February 8, 2018, and pursuant to the terms of the Agreement and Plan of Merger by and among the Issuer, Parent and Abingdon Acquisition Corp. ("Merger Sub") dated December 21, 2017, Merger Sub acquired all of the issued and outstanding shares of Common Stock (the "Shares") for a purchase price of $27.00 per Share (the "Merger"). In connection with the Merger, this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (1) the number of shares of Common Stock of the Issuer underlying such option multiplied by (2) the excess, if any, of $27.00 over the exercise price per share of such option.